Chromoblastomycosis due to *Fonsecaea monophora* misdiagnosed as sporotrichosis and cutaneous tuberculosis in a pulmonary tuberculosis patient

Dongmei Shi a, b, 1, Wei Zhang b, 1, Guixia Lu b, G. Sybren de Hoog c, Guanzhao Liang b, Huan Mei b, Hailin Zheng b, Yongnian Shen b, Weida Liu b, * w

1. Introduction

Chromoblastomycosis is a chronic subcutaneous fungal infection in immunocompetent individuals, clinically characterized by verrucous skin eruptions, most commonly on lower extremities [1]. Among factors affecting clinical outcome, etiological agents have an important position. To date, several species have been proven as a causative agent of the disease, of which *Fonsecaea pedrosi*, *F. monophora*, *Fonsecaea nubica*, *Cladophialaphora carrioni*, *Phialophora verrucosa* and *Rhinocladiella aquaspersa* are common agents. Several *Exophiala* species (*Exophiala jeanselmei*, *Exophiala spinifera* and *Exophiala dermatitidis*) have been confirmed as occasional agents of the disease [2]. A history of mechanical trauma or injury to the site of infection marks the prevalent portal of entry.

In southern China, *Fonsecaea pedrosi* and *F. monophora* are main causative agents causing chromoblastomycosis, and patients generally are immunocompetent [3]. Here, we present a case caused by *F. monophora* in a pulmonary tuberculosis patient without known history of trauma. The agent was isolated from skin scrapings and identified by phenotypic and molecular markers. The patient was managed successfully with oral terbinafine in combination with topical thermotherapy.

2. Case

A 63-year-old male farmer from Jiangxi Province, southern China presented with asymptomatic verrucous plaques covered with scales on the back side of right hand and a small erythematous was on right forearm on 3 January 2016 (at day 0). The lesion had started as an asymptomatic, red papule on the back of his hand, and slowly enlarged over a period of 10 years. Concomitantly, a similar maculopapule appeared on his left forearm. A history of trauma or inoculation was not recalled. Patient was diagnosed as sporotrichosis in a local hospital; however, no response was achieved to drug sensitive test in vitro. Then, because of a suspicion of cutaneous tuberculosis, treatment with oral terbinafine 250 mg daily according to drug sensitive test in vitro in combination with local thermotherapy. The lesions recovered markedly after two month treatment with oral terbinafine at 0.6 g per day for ten months. The pulmonary tuberculosis healed completely. However, there was no improvement in skin lesion, which recovered slightly in summer and enlarged in winter.

One year ago (at day 1 years), the patient’s lesion was diagnosed as sporotrichosis in a local hospital; however, no response was achieved to a 2-month routine course of potassium iodide treatment. Then, because of a suspicion of cutaneous tuberculosis, treatment with intravenous injection of levofloxacin at 0.4 g per
day plus oral rifampicin at 0.6 g per day was resumed for one month (during day-10 months to day-8 months). However, there was no improvement of the lesion.

Physical examination revealed purple, verrucous plaques covered with scales on the back of his right hand. A small (2 × 2 cm) erythematous was seen on right forearm (at day 0) (Fig. 1A and B). Results of routine hematological examination and urine analysis were within normal limits. Serological tests for HIV and anti-nuclear antibodies (e.g., anti-dsDNA antibody and anti-ssDNA antibody) were negative and chest radiography was unremarkable. Histopathology with haematoxylin and eosin staining of the epidermis showed irregular acanthosis, and a granulomatous response with histiocytes, plasma cells, polymorphonuclear cells and giant cells including muriform cells in the dermis (Fig. 2). These results led to a clinical diagnosis of chromoblastomycosis. Direct examination of 10% potassium hydroxide wet mounts from the lesion debris revealed brown muriform cells (Fig. 3A) confirming the clinical diagnosis.

Mycological culture was performed (at day 0). Portions of both skin biopsies and skin debris were inoculated onto culture media attempting to recover the etiologic agent. Primary isolation of the fungus was performed on agar slants of Sabouraud’s glucose agar (SGA) containing chloramphenicol (CMP, 0.125 g/l) and incubated at 25 °C and 37 °C for two weeks. Colonies (OA) were restricted, slightly heaped, powdery to velvety or hairy, olivaceous black; colony reverse olivaceous black. The strain was tolerant to cycloheximide (CHX) and grew well at 25 °C and 37 °C on CHX-containing SGA. Microscopically, conidiophores were suberect, olivaceous brown, apically densely branched. Conidiogenous cells were in dense clusters, with broad, flat, pale pigmented scars. Conidia were barrel-shaped, clustered, often remaining attached, smooth-walled, brown, or falling off as short branchlets. Phialides were occasionally produced (Fig. 3C). The fungus was identified as a Fonsecaea species based on these morphological characteristics.

The isolated agent was reconfirmed by sequencing of ITS 1 and ITS 4 region of rDNA and compared with sequences deposited in GenBank by Blast program and to an edited research database on black fungi maintained at CBS. Based on these analyses, the fungus was identified as Fonsecaea monophora. The isolated agent was deposited in the Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College in Nanjing, Jiangsu, under accession number CMCCf2160004.

At day + 10, the in vitro susceptibility of the strain to eight antifungal agents was determined using the microdilution method in accordance with the guidelines of the Clinical and Laboratory Standards Institute (CLSI) M38A [4]. The minimum inhibitory concentrations (MICs) were defined as the lowest concentration at which no growth occurred which led to the following results: itraconazole, 0.06 μg/ml; ketoconazole, 0.5 μg/ml; fluconazole, 16 μg/ml; miconazole, 2 μg/ml; voriconazole, 0.06 μg/ml; anidulafungin, > 4 μg/ml; amphotericin B, 16 μg/ml; terbinafine, 0.06 μg/ml.

The patient received empirical treatment with oral itraconazole 200 mg and terbinafine 250 mg daily for 2 weeks (during day

Fig. 1. Lesions caused by Fonsecaea monophora on the patient’s right wrist and the back side of right hand, even after treatment with 10% potassium iodide solution for 2 months.

Fig. 2. Chronic granulomatous inflammation: epidermis with irregular acanthosis; dermis consisting of lymphocytes, plasma cells, neutrophils, eosinophils, macrophages, and multinucleated giant cells. Some giant cells containing muriform bodies (periodic acid–Schiff stain; original magnification, × 400).
Based on the antifungal susceptibility testing, itraconazole should be most effective, but since oral itraconazole application induces itching, treatment with oral terbinafine 250 mg daily with terbinafine cream twice per day was continued. Over 2 months of treatment, the skin lesions showed marked reduction (during day +15 to day +30). The drug was well tolerated by the patient without showing any side-effects. Because the agent was not thermotolerant, local thermotherapy was also used, and the patient responded well to the combined therapy.

3. Discussion

Chromoblastomycosis is a chronic subcutaneous mycosis caused by dematiaceous fungi. The disease has been reported worldwide, but is more prevalent in tropical and subtropical regions of Southern Africa, Madagascar, Latin America, East Asia, and Australia [2]. Chromoblastomycosis is caused by several species in the ascomycete order Chaetothyriales, comprising the black yeasts and relatives, mainly Fonsecaea pedrosoi (syn.: Fonsecaea compacta), Rhinocladia aquaspersa, Cladophilophora carrionii, and occasionally Phialophora verrucosa. Agents in Exophiala are highly exceptional and usually cause other types of infection without muriform cells.

Several species are potential etiologic agents of the disease in the endemic areas of southern China, with Fonsecaea species traditionally being referred to as F. pedrosoi [3]. During a recent taxonomic revision of the genus Fonsecaea, three species were recognized to be commonly involved in chromoblastomycosis, viz. F. pedrosoi, F. monophora, and F. nubica. F. monophora, segregated from F. pedrosoi on molecular grounds [5], was shown to have a more variable clinical spectrum than F. pedrosoi: it proved to be a more general opportunistic pathogen, repeatedly causing neurotropic infections, whereas F. pedrosoi and F. nubica are exclusively associated with chromoblastomycosis [6]. While morphological differentiation is difficult, molecular analysis is necessary to reliably identify the fungus down to species level. Recently, Xi et al. re-evaluated 24 isolates from chromoblastomycosis patients that were originally identified as F. pedrosoi [3]. Using rDNA ITS sequencing, 20 of the strains were found to be F. monophora, suggesting that this is the prevalent agent of chromoblastomycosis in southern China. Jiangxi Province has a subtropical monsoon climate, which typically promotes the occurrence of Fonsecaea species, whereas Cladophilophora agents of the disease are restricted to arid climate zones [2].

The clinical appearance of chromoblastomycosis is polymorphic. Etiologic agents are hypothesized to gain entrance through the skin by traumatic implantation of contaminated material. The majority of lesions are observed on extremities of outdoor workers. Queiroz-Telles et al. [7] described five types of lesions: nodular, tumorous, verrucous, cicatricial and plaque, while additional types were proposed in further literature. The fungus causing chromoblastomycosis usually is restricted to subcutaneous tissue; cutaneous dissemination may develop as a result of self-inoculation from the original lesion, perhaps also by local hematogenous or lymphatic spread. In later stages of disease, marked extension to other body parts is common. The host immune status is believed to play a role in the clinical evolution of this disorder.
leading to either mild or severe symptoms, even though most cases develop in otherwise healthy individuals; infections caused by *F. monophora* in immunocompromised patients are very rare [8].

The origin of infection in our case remains obscure. We presume that the portal of entry of the fungus must have been through minor trauma, even if such a history was denied. We were not able to trace back the patient’s immunological status when he was infected by the fungus. Because patient had a double infection with *Fonsecaea monophora* and *Mycobacterium tuberculosis*, we presume that the patient was under temporary immunosuppression, which likely contributed to the spread of the fungus to cause the right forearm lesion.

Because of clinical polymorphic appearance of chromoblastomycosis, it is difficult to diagnose the disease on the basis of clinical appearance only. Histopathology is identical in all types of chromoblastomycosis, being the hallmark of the disease but without species differentiation. Polymorphonuclear cells and giant cells are formed in the dermis. Muriform cells were easily recognized in routine haematoxylin-eosin stain, but were also visible in KOH wet mounts. In the present case, patient was initially diagnosed with sporotrichosis judging from clinical appearance only, while also an erroneous diagnosis of cutaneous tuberculosis was made because he was unresponsive to potassium iodide treatment and had a history of pulmonary tuberculosis.

Chromoblastomycosis is difficult to treat and relapses may occur. Therefore it is important to consider personalized treatment of the patient based on the severity of the disease and clinical and histopathological features. Nowadays, therapy is based on a few open trials and expert opinion. Itraconazole, either as monotherapy or in combination with other drugs or physical methods, is widely used [9,10]. Recently, the combination of antifungals with photodynamic therapy has successfully been employed in patients [9,10]. Recently, the combination of antifungals with photodynamic therapy has successfully been employed in patients [9,10]. Recently, the combination of antifungals with photodynamic therapy has successfully been employed in patients [9,10]. Recently, the combination of antifungals with photodynamic therapy has successfully been employed in patients [9,10]. Recently, the combination of antifungals with photodynamic therapy has successfully been employed in patients [9,10].

In conclusion, we describe a rare case of chromoblastomycosis due to *Fonsecaea monophora*, in a patient with pulmonary tuberculosis who was initially misdiagnosed with sporotrichosis and skin tuberculosis. To correctly diagnose these infections, pathologists need to be aware of chromoblastomycosis and the characteristics of sclerotic body morphology. In addition, molecular diagnostics should be encouraged to identify the *Fonsecaea* species involved. Finally, the treatment should be adjusted according to antifungal drug sensitivity testing and a prolonged period of treatment may help to prevent recurrence.

### Conflict of interest

The authors have no conflict of interests in connection with this study.

### Acknowledgements

This work was supported by grants from the Natural Science Foundation of Shandong province, China (NM. ZR2015HL127), the National Natural Science Foundation of China (NM. 81401653), and the National Key Basic Research Program of China (NM. 2013CB531605).

### References

[1] M.Z. Doymaz, M.F. Seyithanoglu, İ. Hakyemez, B.S. Gultepe, S. Cevik, T. Aslan, A case of cerebral phaeohyphomycosis caused by *Fonsecaea monophora*, a neurotropic dematiaceous fungus, and a review of the literature, *Mycoses* 58 (3) (2015) 187–192.

[2] S. Deng, C.K. Tsui, A.H.G. van den Ende, et al., Global spread of human chromoblastomycosis is driven by recombinant Cladophialophora carrionii and predominately clonal *Fonsecaea* species, *PLoS Negl. Trop. Dis.* 9 (10) (2015) e0004004.

[3] L. Xi, J. Sun, C. Lu, et al., Molecular diversity of *Fonsecaea* (Chaetothyriales) causing chromoblastomycosis in southern China, *Med. Mycol.* 47 (1) (2009) 27–33.

[4] E. Pinto, M. Lago, L. Branco, L.A. Vale-Silva, M.D. Pinheiro, Evaluation of Etest performed in Mueller-Hinton agar supplemented with glucose for antifungal susceptibility testing of clinical isolates of filamentous fungi, *Mycopathologia* 177 (3–4) (2014) 157–165.

[5] G.S. De Hoog, A. Attili-Angelis, V.A. Vicente, A.H. Van Den Ende, F. Queiroz-Telles, Molecular ecology and pathogenic potential of *Fonsecaea* species, *Med. Mycol.* 42 (5) (2004) 405–416.

[6] S. Koo, M. Klopas, F.M. Marty, *Fonsecaea monophora* cerebral phaeohyphomycosis: case report of successful surgical excision and voriconazole treatment and review, *Med. Mycol.* 48 (5) (2010) 769–774.

[7] F. Queiroz-Telles, P. Esterrer, M. Perez-Blanco, R.G. Vitale, C.G. Salgado, A. Bonifaz, Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment, *Med. Mycol.* 47 (1) (2009) 3–15.

[8] H. Tan, Y. Xu, X.M. Lan, Y.G. Wu, C.J. Zhou, X.C. Yang, Chromoblastomycosis due to *Fonsecaea monophora* in a man with nephritic syndrome, *Myopathologia* 179 (5–6) (2015) 467–472.

[9] J.M. ZHANG, X.I. LY, H. ZHANG, et al., Synergistic effects of terbinafine and itraconazole on clinical isolates of *Fonsecaea monophora*, *Eur. J. Dermatol.* 19 (5) (2009) 451–455.

[10] M.J. Najafzadeh, A. Rezusta, M.J. Cameo, et al., Successful treatment of chromoblastomycosis of 36 years duration caused by *Fonsecaea monophora*, *Med. Mycol.* 48 (2) (2010) 390–393.

[11] Y. Hu, X. Huang, S. Lu, et al., Photodynamic therapy combined with terbinafine against chromoblastomycosis and the effect of PDT on *Fonsecaea monophora* in vitro, *Mycopathologia* 179 (1–2) (2015) 103–109.